SCYNEXIS ( NASDAQ:SCYX ) Second Quarter 2025 Results Key Financial Results Net loss: US$6.89m (loss narrowed by 52...
17 hours ago

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Wednesday reported a loss of $6.9 million in its second quarter.
1 day ago

SCYNEXIS reports first patient dosed in Phase 3 study, milestone payments from GSK, and ongoing fina.
2 days ago

SCYNEXIS (NASDAQ: SCYX) reported Q2 2025 financial results and significant corporate developments. The company achieved a major milestone...
2 days ago

SCYNEXIS Inc ( ($SCYX) ) has released its Q2 earnings. Here is a breakdown of the information SCYNEXIS Inc presented to its investors.
1 day ago

Reports Q2 revenue $1.36M, consensus $154000. “We are excited about the continued progress of our second-generation fungerp candidate,...
23 hours ago

Scynexis (SCYX) reported its fiscal 2025 Q2 earnings on August 13, 2025, with the company narrowing its losses and posting a significant...
1 day ago

Scynexis has resumed a phase 3 study in another use. The dosing of the first new patient in the MARIO study triggers a $10 million milestone payment from GSK.
2 months ago

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Scynexis Inc. (SCYX) on Wednesday reported a loss of $6.9 million in its second quarter.
2 days ago

SCYNEXIS Inc (($SCYX)) announced an update on their ongoing clinical study. Study Overview: SCYNEXIS Inc. is conducting a Phase 3, multicenter, ran...
1 day ago